Induction of Tolerance Through Mixed Chimerism for Composite Tissue Allotransplantation: Insights, Problems and Solutions

[1]  P. Chilton,et al.  Addition of Cyclophosphamide to T-cell Depletion–Based Nonmyeloablative Conditioning Allows Donor T-cell Engraftment and Clonal Deletion of Alloreactive Host T-cells After Bone Marrow Transplantation , 2007, Transplantation.

[2]  V. Gorantla,et al.  Creating a hand transplant program. , 2007, Clinics in plastic surgery.

[3]  D. Schaubel,et al.  Evaluating the Survival Benefit of Kidney Retransplantation , 2006, Transplantation.

[4]  Q Han,et al.  Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells , 2006, Bone Marrow Transplantation.

[5]  H. Deeg,et al.  Optimization of allogeneic transplant conditioning: not the time for dogma , 2006, Leukemia.

[6]  M. Cunningham,et al.  Investigation of risk acceptance in hand transplantation. , 2005, The Journal of hand surgery.

[7]  P. Chilton,et al.  Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment , 2005, The Journal of experimental medicine.

[8]  Angela Panoskaltsis-Mortari,et al.  Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 , 2004, The Journal of Immunology.

[9]  P. Chilton,et al.  Production of Donor T Cells Is Critical for Induction of Donor-Specific Tolerance and Maintenance of Chimerism1 , 2004, The Journal of Immunology.

[10]  S. Ildstad,et al.  Facilitating cells as a venue to establish mixed chimerism and tolerance , 2003, Pediatric transplantation.

[11]  R. Foster,et al.  Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade , 2003, Transplantation.

[12]  V. Gorantla,et al.  Composite tissue allotransplantation in chimeric hosts: part I. prevention of graft-versus-host disease1 , 2003, Transplantation.

[13]  L. Luznik,et al.  Nonmyeloablative alternative donor transplants , 2003, Current opinion in oncology.

[14]  M. Gilliet,et al.  Generation of Human CD8 T Regulatory Cells by CD40 Ligand–activated Plasmacytoid Dendritic Cells , 2002, The Journal of experimental medicine.

[15]  S. Ildstad,et al.  CD8+, αβ-TCR+, and γδ-TCR+ Cells in the Recipient Hematopoietic Environment Mediate Resistance to Engraftment of Allogeneic Donor Bone Marrow1 , 2002, The Journal of Immunology.

[16]  P. Chilton,et al.  The role of alphabeta- and gammadelta-T cells in allogenic donor marrow on engraftment, chimerism, and graft-versus-host disease. , 2001, Transplantation.

[17]  S. Pham,et al.  A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts. , 2001, The Annals of thoracic surgery.

[18]  M. Sykes,et al.  Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment , 2000, Nature Medicine.

[19]  M. Sykes,et al.  Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. , 1999, Transplantation.

[20]  W. Chambers,et al.  A partial conditioning approach to achieve mixed chimerism in the rat: depletion of host natural killer cells significantly reduces the amount of total body irradiation required for engraftment. , 1999, Transplantation.

[21]  S. Pham,et al.  Simultaneous donor bone marrow and cardiac transplantation: can tolerance be induced with the development of chimerism? , 1999, Current opinion in cardiology.

[22]  A. Demetris,et al.  Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts. , 1998, Circulation.

[23]  R. Foster,et al.  Donor-specific tolerance induction in composite tissue allografts. , 1998, American journal of surgery.

[24]  Y. Colson,et al.  A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment. , 1998, Experimental hematology.

[25]  Y. Colson,et al.  Mixed allogeneic chimerism prevents obstructive airway disease in a rat heterotopic tracheal transplant model. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  V. Snell,et al.  Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. , 1998, Blood.

[27]  I. Weissman,et al.  Tolerance of allogeneic heart grafts in mice simultaneously reconstituted with purified allogeneic hematopoietic stem cells. , 1998, Transplantation.

[28]  Y. Colson,et al.  Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. , 1996, Journal of immunology.

[29]  P. Fiedor,et al.  Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. , 1996, The American surgeon.

[30]  Y. Colson,et al.  Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts. , 1995, Transplantation.

[31]  G. Freeman,et al.  Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. , 1993, Science.

[32]  E. Estey,et al.  Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. , 1993, Seminars in oncology.

[33]  P. Wijermans,et al.  Severe immunodeficiency in patients treated with fludarabine monophosphate , 1993, European journal of haematology.

[34]  S. Wren,et al.  MIXED ALLOGENEIC RECONSTITUTION (A+B→A) TO INDUCE DONOR‐SPECIFIC TRANSPLANTATION TOLERANCE: PERMANENT ACCEPTANCE OF A SIMULTANEOUS DONOR SKIN GRAFT , 1991, Transplantation.

[35]  T. Ghayur,et al.  Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction. Relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations. , 1987, Transplantation.

[36]  T. Ghayur,et al.  KINETICS OF NATURAL KILLER CELLCYTOTOXICITY REACTION: Relationship Between Natural Killer Cell Activity, T and B Cell Activity, and Development of Histopathological Alterations , 1987 .

[37]  J. Bluestone,et al.  Alloresistance to engraftment of allogeneic donor bone marrow is mediated by an Lyt-2+ T cell in mixed allogeneic reconstitution (C57BL/10Sn + B10.D2/nSn----C57BL/10Sn) , 1986, The Journal of experimental medicine.

[38]  J. Bluestone,et al.  Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10). , 1986, Journal of immunology.

[39]  D. Sachs,et al.  Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts , 1984, Nature.

[40]  J. Sprent,et al.  Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow , 1978, The Journal of experimental medicine.

[41]  P. Medawar,et al.  ‘Actively Acquired Tolerance’ of Foreign Cells , 1953, Nature.

[42]  P. K. Subbanna,et al.  Mesenchymal stem cells for treating GVHD: in-vivo fate and optimal dose. , 2007, Medical hypotheses.

[43]  J. Aschan.  Allogeneic haematopoietic stem cell transplantation: current status and future outlook. , 2006, British medical bulletin.

[44]  F. Wei,et al.  Heterotopic hindlimb allotransplantation in rats: An alternative model for immunological research in composite‐tissue allotransplantation , 2005, Microsurgery.

[45]  V. Gorantla,et al.  Mixed allogeneic chimerism and tolerance to composite tissue allografts , 2000, Microsurgery.

[46]  Y. Colson,et al.  Mixed hematopoietic chimerism induces donor-specific tolerance for lung allografts in rodents. , 1999, American journal of respiratory and critical care medicine.